One-liner#

Hypertension management requires accurate diagnosis (confirm with out-of-office readings), risk stratification (10-year ASCVD risk), BP targets by population (<130/80 for most, individualized for elderly/frail), and medication selection guided by compelling indications (ACE-I/ARB for diabetes/CKD, thiazide/CCB for Black patients, beta-blockers for CAD/HF).

Quick nav#

• Definition and epidemiology
• Pathophysiology
• Clinical presentation
• Diagnostic workup
• Treatment
• Patient education
• Prognosis and monitoring
• Special populations
• When to refer
• Smartphrase snippets
• Related pages

Definition and epidemiology#

Diagnostic criteria#

ACC/AHA 2017 Classification:

• Normal: SBP <120 AND DBP <80
• Elevated: SBP 120-129 AND DBP <80
• Stage 1 HTN: SBP 130-139 OR DBP 80-89
• Stage 2 HTN: SBP ≥140 OR DBP ≥90
• Hypertensive crisis: SBP >180 and/or DBP >120

Diagnosis requires:

• Average of ≥2 readings on ≥2 occasions
• Proper technique: seated 5 min, back supported, feet flat, arm at heart level, appropriate cuff size
• Confirm with out-of-office measurements (home BP or ambulatory BP monitoring) before starting treatment

White coat hypertension: Office BP ≥130/80 but home/ABPM <130/80 (prevalence ~15-30%) Masked hypertension: Office BP <130/80 but home/ABPM ≥130/80 (prevalence ~10-15%; higher CV risk)

Epidemiology#

Prevalence is approximately 47% of US adults (116 million). Only 24% have BP controlled to <130/80. Leading modifiable risk factor for cardiovascular disease, stroke, CKD, and death worldwide. Risk factors include age >55, Black race, family history, obesity, high sodium diet, physical inactivity, excessive alcohol, and chronic stress. Lifetime risk of developing HTN is approximately 90% for adults who reach age 55.

Pathophysiology#

Mechanism (clinical understanding)#

Primary (essential) hypertension (90-95% of cases): Multifactorial: genetic predisposition + environmental factors (sodium intake, obesity, stress) lead to sustained elevation in systemic vascular resistance. Key mechanisms include:

• RAAS activation: Angiotensin II causes vasoconstriction, aldosterone-mediated sodium retention, and vascular remodeling
• Sympathetic overdrive: Increased catecholamines raise HR and vasoconstriction
• Endothelial dysfunction: Reduced nitric oxide, increased oxidative stress
• Arterial stiffening: Loss of elasticity with age and chronic pressure load

Vascular remodeling: Chronic elevated pressure causes smooth muscle hypertrophy, collagen deposition, and arterial stiffening. This increases systolic BP and pulse pressure, particularly in elderly patients.

End-organ damage mechanisms:

• Heart: Pressure overload → LVH → diastolic dysfunction → HFpEF; also accelerates CAD
• Kidneys: Glomerular hypertension → nephrosclerosis → CKD; proteinuria indicates damage
• Brain: Small vessel disease → lacunar infarcts, white matter changes, vascular dementia; also increases hemorrhagic and ischemic stroke risk
• Eyes: Hypertensive retinopathy (AV nicking, hemorrhages, exudates, papilledema)
• Vasculature: Accelerates atherosclerosis; increases aortic aneurysm and dissection risk

Secondary hypertension (5-10% of cases): Identifiable cause; suspect if onset <30 or >55, resistant HTN, sudden worsening, or specific clinical features.

How to explain to patients#

Your blood pressure is the force of blood pushing against your artery walls. When this pressure stays high over time, it damages your blood vessels and organs like your heart, kidneys, and brain.

Think of it like a garden hose. If the pressure is too high for too long, the hose walls get stiff and damaged. The same thing happens to your arteries.

High blood pressure usually has no symptoms, which is why it is called the silent killer. You can feel perfectly fine while damage is happening inside. That is why checking your blood pressure regularly and taking your medications is so important.

The good news is that lowering your blood pressure significantly reduces your risk of heart attack, stroke, and kidney disease. Every 10-point drop in the top number cuts your risk of these problems by about 20%.

Clinical presentation#

Characteristic symptoms#

Most patients are asymptomatic—HTN is typically detected on routine screening. This is why it is called the “silent killer.”

Symptoms when present (usually severe or longstanding HTN):

• Headache (classically occipital, morning; more common with severe HTN)
• Dizziness, lightheadedness
• Visual changes (blurred vision)
• Epistaxis (not clearly caused by HTN, but often prompts BP check)
• Dyspnea on exertion (may indicate LVH or HF)
• Chest discomfort (may indicate LVH or CAD)

Symptoms suggesting secondary cause:

• Paroxysmal headache, palpitations, diaphoresis (pheochromocytoma)
• Muscle weakness, cramps (hypokalemia from primary aldosteronism)
• Snoring, daytime somnolence, witnessed apneas (OSA)
• Weight gain, striae, easy bruising (Cushing’s)

Physical exam findings#

Blood pressure measurement:

• Use appropriate cuff size (bladder encircles 80% of arm)
• Patient seated 5 minutes, back supported, feet flat, arm at heart level
• No caffeine, exercise, or smoking for 30 minutes prior
• Average of 2 readings, 1-2 minutes apart
• Check both arms initially; use arm with higher reading subsequently

Target organ damage signs:

• Cardiac: S4 gallop (LVH), displaced PMI, murmurs
• Vascular: Diminished peripheral pulses, bruits (carotid, renal, femoral)
• Fundoscopic: AV nicking, copper/silver wiring, hemorrhages, exudates, papilledema
• Neurologic: Usually normal unless prior stroke

Signs suggesting secondary cause:

• Abdominal bruit (renal artery stenosis)
• Delayed femoral pulses, BP differential arms/legs (coarctation)
• Truncal obesity, striae, moon facies (Cushing’s)
• Thyroid enlargement, tremor, tachycardia (hyperthyroidism)

Red flags#

Require urgent evaluation (hypertensive emergency):

• Severe headache with altered mental status (hypertensive encephalopathy)
• Chest pain or dyspnea (ACS, aortic dissection, acute HF)
• Focal neurologic deficits (stroke)
• Visual changes with papilledema (malignant HTN)
• Acute kidney injury (hypertensive nephropathy)
• BP >180/120 with any of the above symptoms

Diagnostic workup#

Initial evaluation#

All patients with elevated BP:

• Confirm diagnosis: Average of ≥2 readings on ≥2 occasions; confirm with home BP or ABPM before starting medications
• BMP: Baseline Cr, K, Na, glucose (CKD, electrolyte abnormalities, diabetes)
• Lipid panel: Assess CV risk; guide statin therapy
• Fasting glucose or A1c: Screen for diabetes (common comorbidity)
• Urinalysis: Proteinuria, hematuria (kidney damage)
• ECG: LVH, prior MI, arrhythmia

Calculate 10-year ASCVD risk (ACC/AHA Pooled Cohort Equations):

• Guides treatment intensity and statin therapy
• Risk ≥10% favors pharmacotherapy even at Stage 1 HTN

Home BP monitoring:

• Validated oscillometric device (upper arm preferred)
• Measure twice daily (morning and evening) for 1-2 weeks
• Average of readings (exclude first day)
• Home BP ≥130/80 confirms HTN; <130/80 suggests white coat effect

Ambulatory BP monitoring (ABPM):

• Gold standard for diagnosis; 24-hour average
• Confirms white coat HTN, masked HTN, nocturnal HTN
• Daytime average ≥130/80 or 24-hour average ≥125/75 confirms HTN

Confirmatory testing#

Target organ damage assessment (consider in all patients):

• Urine albumin/creatinine ratio (UACR): Microalbuminuria (30-300 mg/g) indicates early kidney damage; guides ACE-I/ARB use
• Echocardiogram: If clinical suspicion for LVH, HF, or valvular disease; not routine for uncomplicated HTN
• Fundoscopic exam: Assess for hypertensive retinopathy; often deferred to optometry/ophthalmology

Secondary HTN workup (when indicated):

When to refer for specialist workup#

• Suspected secondary HTN (positive screening test or high clinical suspicion)
• Resistant HTN (uncontrolled on 3 agents including diuretic at optimal doses)
• Hypertensive emergency or urgency with end-organ damage
• Pregnancy with HTN (high-risk OB)
• Complex comorbidities requiring subspecialty input

What NOT to order#

• Routine echocardiogram in uncomplicated HTN without clinical suspicion for LVH or HF—ECG is sufficient for initial screening
• Extensive secondary HTN workup in typical primary HTN (age 30-55, no resistant HTN, no clinical clues)
• Renal artery imaging without clinical suspicion (bruit, flash pulmonary edema, Cr rise with ACE-I)
• Plasma metanephrines without paroxysmal symptoms or adrenal mass—very low yield
• Repeat ABPM if diagnosis already confirmed

Treatment#

Goals of therapy#

BP targets (ACC/AHA 2017):

Treatment thresholds:

• Stage 1 HTN (130-139/80-89): Lifestyle first; add medication if ASCVD risk ≥10% or known CVD/DM/CKD
• Stage 2 HTN (≥140/90): Lifestyle + medication

Non-pharmacologic management#

Lifestyle modifications can lower SBP by 5-15 mmHg; should be recommended for ALL patients regardless of medication use.

Specific counseling points:

• “Reducing salt is one of the most effective things you can do. Most salt comes from processed and restaurant foods, not the salt shaker.”
• “The DASH diet is as effective as one blood pressure medication.”
• “Losing even 10 pounds can significantly lower your blood pressure.”
• “Regular exercise helps even if you don’t lose weight.”

Pharmacologic management#

First-line agents (choose based on compelling indications):

Second-line and add-on agents:

Medication selection by compelling indication:

• Diabetes: ACE-I or ARB (renal protection; reduces proteinuria)
• CKD with proteinuria: ACE-I or ARB (slows CKD progression; reduces proteinuria)
• Heart failure (HFrEF): ACE-I/ARB/ARNI + beta-blocker + MRA + SGLT2i (GDMT for mortality benefit)
• CAD/post-MI: ACE-I + beta-blocker (secondary prevention)
• Stroke/TIA: ACE-I + thiazide (secondary prevention per PROGRESS trial)
• Black patients: CCB or thiazide (better response; ACE-I/ARB less effective as monotherapy)
• Elderly: CCB or thiazide (well-tolerated; effective)
• Migraine: Beta-blocker—propranolol, metoprolol (dual benefit)
• BPH: Alpha-blocker—doxazosin (dual benefit; not first-line for HTN alone)
• Pregnancy: Labetalol, nifedipine, methyldopa (safe in pregnancy; avoid ACE-I/ARB)

Combination therapy:

• Most patients need 2+ agents to reach goal
• Start with 2 agents if BP ≥20/10 above goal (Stage 2 HTN)
• Effective combinations: ACE-I/ARB + CCB, ACE-I/ARB + thiazide, CCB + thiazide
• Avoid: ACE-I + ARB (no added benefit, more side effects)

Patient counseling points#

For ACE-I/ARB:

• “This medicine protects your heart and kidneys. It’s especially important if you have diabetes or kidney disease.”
• “A dry cough happens in about 1 in 10 people on ACE inhibitors. If it bothers you, we can switch to a similar medicine (ARB) that doesn’t cause cough.”
• “We’ll check your kidney function and potassium with a blood test 1-2 weeks after starting.”

For thiazides:

• “This water pill helps your body get rid of extra salt and fluid, which lowers blood pressure.”
• “Take it in the morning so you’re not up at night to urinate.”
• “It can lower your potassium, so eat potassium-rich foods like bananas and oranges.”

For CCBs:

• “This medicine relaxes your blood vessels to lower pressure.”
• “Ankle swelling is common—it’s not dangerous but can be bothersome. Elevating your legs helps.”

For beta-blockers:

• “This medicine slows your heart rate and reduces the heart’s workload.”
• “Don’t stop it suddenly—we need to taper it gradually.”
• “It may make you feel tired at first; this usually improves.”

Monitoring and follow-up#

Initial phase (first 3-6 months):

• Follow-up every 2-4 weeks until BP at goal
• Check Cr, K at 1-2 weeks after starting/changing ACE-I/ARB or diuretic
• Assess for side effects at each visit
• Encourage home BP monitoring

Stable phase:

• Follow-up every 3-6 months once at goal
• Annual labs: BMP, lipid panel, UA, UACR (if diabetic or CKD)
• Annual ECG if LVH or cardiac symptoms
• Reassess CV risk annually

Home BP monitoring targets:

• Average home BP <130/80 (corresponds to office <130/80)
• Measure twice daily (morning and evening) for 1 week before visits
• Bring log to appointments

Patient education#

What is this condition?#

Blood pressure is the force of blood pushing against your artery walls. When this force stays too high over time, it is called high blood pressure or hypertension.

High blood pressure is very common. About half of all adults have it. It usually causes no symptoms, which is why it is called the silent killer. You can feel perfectly fine while it is damaging your heart, kidneys, and brain.

The good news is that high blood pressure can be controlled with lifestyle changes and medications. Lowering your blood pressure greatly reduces your risk of heart attack, stroke, and kidney disease.

What you can do#

Check your blood pressure at home. Use an upper arm monitor. Check it twice a day, morning and evening. Write down the numbers and bring them to your appointments.

Reduce salt in your diet. Most salt comes from processed foods, restaurant meals, and canned foods. Read nutrition labels. Aim for less than 2300 mg of sodium per day.

Eat more fruits, vegetables, and whole grains. The DASH diet can lower blood pressure as much as one medication.

Stay active. Aim for 30 minutes of brisk walking or other exercise most days of the week.

Maintain a healthy weight. Losing even 10 pounds can lower your blood pressure.

Limit alcohol. Men should have no more than 2 drinks per day. Women should have no more than 1 drink per day.

Take your medications every day, even when you feel fine. Do not stop or skip doses without talking to your doctor.

When to seek care#

Call your doctor if your home blood pressure readings are consistently above 180/120.

Call your doctor if you have new or worsening headaches, dizziness, or vision changes.

Go to the emergency room if you have severe headache with confusion or difficulty speaking. Go if you have chest pain or shortness of breath. Go if you have sudden weakness or numbness on one side of your body. Go if you have sudden severe back pain.

Questions to ask your doctor#

What is my blood pressure goal? How often should I check my blood pressure at home? What side effects should I watch for with my medications? Do I need any tests to check for organ damage? Are there any foods or medications I should avoid?

Prognosis and monitoring#

Expected course#

With treatment:

• Most patients achieve BP control with 1-3 medications
• CV risk reduction is proportional to BP lowering: ~20% reduction in major CV events per 10 mmHg SBP reduction
• SPRINT trial: intensive control (SBP <120) reduced CV events by 25% and mortality by 27% vs standard control (<140)
• Benefits seen within 1-2 years of treatment

Without treatment:

• Progressive end-organ damage over years to decades
• 2-3x increased risk of stroke, MI, HF, CKD
• Accelerated atherosclerosis
• Hypertensive emergencies

Factors affecting prognosis:

• Degree of BP elevation
• Duration of HTN
• Presence of target organ damage (LVH, CKD, retinopathy)
• Comorbidities (diabetes, dyslipidemia, smoking)
• Medication adherence

Monitoring parameters#

Complications to watch for#

Cardiovascular:

• LVH (leads to HFpEF, arrhythmias)
• CAD and MI
• Atrial fibrillation
• Heart failure
• Aortic aneurysm and dissection

Cerebrovascular:

• Ischemic stroke
• Hemorrhagic stroke
• Vascular dementia
• Lacunar infarcts

Renal:

• Hypertensive nephrosclerosis
• CKD progression
• Proteinuria

Ophthalmologic:

• Hypertensive retinopathy
• Vision loss (severe cases)

Special populations#

Elderly/geriatric#

Treatment considerations:

• HTN treatment reduces CV events even in patients >80 years (HYVET trial)
• Start at lower doses; titrate more slowly
• More sensitive to orthostatic hypotension—check standing BP
• Higher risk of falls with aggressive BP lowering
• Polypharmacy: review all medications; simplify regimens

BP targets:

• Age 65-79: <130/80 if tolerated; may accept <140/90 if orthostatic symptoms or falls
• Age ≥80 or frail: <140-150 systolic; prioritize avoiding hypotension and falls
• Individualize based on functional status, life expectancy, patient preferences

Medication considerations:

• CCBs (amlodipine) and thiazides: well-tolerated, effective first-line
• ACE-I/ARB: use if compelling indication (DM, CKD, HF); start low
• Beta-blockers: avoid as first-line unless compelling indication; can cause fatigue, bradycardia
• Alpha-blockers (doxazosin): avoid as first-line (orthostatic hypotension, falls)—Beers criteria
• Clonidine: avoid if possible (CNS effects, rebound)—Beers criteria

Dose adjustments:

• Lisinopril: start 2.5-5 mg daily
• Amlodipine: start 2.5 mg daily
• Chlorthalidone: start 12.5 mg daily; max 25 mg
• Metoprolol: start 12.5-25 mg daily

Chronic kidney disease#

BP target: <130/80 (KDIGO 2021); slows CKD progression

Medication adjustments:

Special considerations:

• ACE-I/ARB: first-line if proteinuria (UACR >30 mg/g); accept Cr rise up to 30%
• Monitor K closely with ACE-I/ARB + MRA combination
• Thiazides less effective when eGFR <30; switch to loop diuretics
• Avoid NSAIDs (worsen renal function, reduce ACE-I efficacy)
• Coordinate with nephrology if eGFR <30 or rapidly declining

Other populations#

Diabetes:

• BP target <130/80 (ADA 2023)
• ACE-I or ARB first-line (renal protection, reduces proteinuria)
• SGLT2 inhibitors: BP-lowering effect (~5 mmHg); cardiorenal benefits
• Avoid thiazides at high doses (worsen glucose control)

Heart failure:

• HFrEF: ACE-I/ARB/ARNI + beta-blocker + MRA + SGLT2i (GDMT)
• HFpEF: diuretics for congestion; SGLT2i; aggressive BP control
• Avoid non-dihydropyridine CCBs (diltiazem, verapamil) in HFrEF

CAD/post-MI:

• ACE-I + beta-blocker for secondary prevention
• BP target <130/80

Stroke/TIA:

• ACE-I + thiazide for secondary prevention (PROGRESS trial)
• BP target <130/80

Pregnancy:

• Avoid ACE-I, ARB (teratogenic)
• Safe agents: labetalol, nifedipine, methyldopa
• Target BP <140/90 (or <135/85 per some guidelines)
• Requires high-risk OB management

Black patients:

• Higher prevalence, earlier onset, more severe HTN
• CCB or thiazide preferred as initial monotherapy (better response than ACE-I/ARB)
• ACE-I/ARB still indicated if compelling indication (DM, CKD, HF)
• Often require combination therapy

Polypharmacy considerations:

• NSAIDs: avoid—cause fluid retention, worsen renal function, reduce ACE-I efficacy
• Decongestants (pseudoephedrine): avoid—raise BP
• Stimulants (ADHD medications): use cautiously; monitor BP
• Steroids: can raise BP; monitor
• Drug interactions: ACE-I + K supplements or K-sparing diuretics → hyperkalemia

When to refer#

Specialist referral criteria#

Cardiology referral:

• Suspected secondary HTN with cardiac etiology (coarctation)
• LVH with symptoms or arrhythmia
• HF management
• Resistant HTN with cardiac complications

Nephrology referral:

• Suspected renal artery stenosis
• CKD with eGFR <30 or rapidly declining
• Resistant HTN with renal involvement
• Significant proteinuria (UACR >300 mg/g)

Endocrinology referral:

• Suspected primary aldosteronism (positive ARR)
• Suspected pheochromocytoma (elevated metanephrines)
• Suspected Cushing’s syndrome
• Suspected thyroid disease causing HTN

Hypertension specialist referral:

• Resistant HTN (uncontrolled on 3+ agents including diuretic)
• Complex secondary HTN workup
• Severe or refractory HTN

Sleep medicine referral:

• Suspected OSA (high STOP-BANG score, symptoms)

Urgency levels#

Smartphrase snippets#

HTN, controlled: HTN, controlled on current regimen. Home BP averaging 125/78; no end-organ symptoms. Continue lisinopril 20 mg daily; f/u 6 months.

HTN, uncontrolled: HTN, uncontrolled with office BP 152/94 and home BP averaging 148/92. Increasing amlodipine from 5 mg to 10 mg daily; reinforced sodium restriction. Recheck BP in 4 weeks.

HTN, new diagnosis: New diagnosis Stage 2 HTN with office BP 156/96 confirmed on repeat. Started lisinopril 10 mg daily; BMP, lipid panel, UA, ECG ordered. Discussed lifestyle modifications and home BP monitoring; f/u 2-4 weeks.

Resistant HTN: Resistant HTN on 3-drug regimen with office BP 148/92 despite confirmed adherence. Adding spironolactone 25 mg daily; check K, Cr in 1 week. Secondary HTN workup initiated; f/u 4 weeks.

Related pages#

• Hypertensive Urgency (complaint) — acute management of severely elevated BP without end-organ damage
• Chest Pain (complaint) — HTN is risk factor for CAD; hypertensive emergency can present with chest pain
• Edema (complaint) — chronic uncontrolled HTN can lead to HF with edema
• Syncope (complaint) — antihypertensive medications can cause orthostatic hypotension
• Heart Failure (problem) — HTN is major cause of HFpEF; GDMT overlaps with HTN treatment
• Coronary Artery Disease (problem) — HTN accelerates atherosclerosis; shared risk factor management
• Atrial Fibrillation (problem) — HTN is leading risk factor for AF; shared management considerations
• Hyperlipidemia (problem) — shared CV risk factor; often co-managed for ASCVD prevention
• Obstructive Sleep Apnea (problem) — OSA is leading cause of resistant HTN; screen all resistant HTN patients
• Type 2 Diabetes (problem) — common comorbidity; ACE-I/ARB preferred; SGLT2i benefits both (coming soon)
• CKD (problem) — HTN causes and accelerates CKD; ACE-I/ARB for renal protection (coming soon)